MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1126/sciadv.adi9885

Медицинская библиотека · Science advances · 2025

Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome.

Hargarten Jessica C, Ssebambulidde Kenneth, Anjum Seher H, Vaughan Malcolm J, Xu Jintao, Ganguly Anutosh, Dulek Brittany, Otaizo-Carrasquero Francisco, Song Brian, Tao Sijia, Park Yoon-Dong, Scott Terri L, Höltermann Tracey-Ann, Schinazi Raymond F, Chittiboina Prashant, Billioux Bridgette Jeanne, Hammoud Dima A, Olszewski Michal A, Williamson Peter R

СтатьяНаблюдательное исследованиеResearch Support, N.I.H., IntramuralПеревод в очереди

Аннотация

Therapies to reduce neuroinflammation following resolution of acute central nervous system (CNS) infections are urgently needed, particularly for patients with non-HIV-associated cryptococcal meningoencephalitis complicated by a postinfectious inflammatory response syndrome (cPIIRS). To identify druggable targets in cPIIRS, patient cerebral spinal fluid samples underwent transcriptional analysis, revealing a Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway dominance in neuroinflammatory gene signatures. MurinecPIIRS models recapitulated this pathway predominance and treatment with the JAK inhibitor ruxolitinib, confirmed a mechanistic requirement for this pathway in disease pathology. Ruxolitinib treatment improved markers of neuronal damage, reduced activated T cell and myeloid cells, and improved weight. On the basis of these findings, we conducted a first-in-human ruxolitinib treatment of patients with cPIIRS (NCT00001352). Ruxolitinib treatment of six patients led to demonstrated tolerability, reductions in inflammatory biomarkers and activated immune cells, and improved brain imaging. These results advocate for pathway-instructed therapeutics in neuroinflammatory diseases and endorse JAK inhibitors in further clinical studies of cPIIRS.

Для цитирования: Hargarten Jessica C, Ssebambulidde Kenneth, Anjum Seher H, Vaughan Malcolm J, Xu Jintao, Ganguly Anutosh, Dulek Brittany, Otaizo-Carrasquero Francisco, Song Brian, Tao Sijia, Park Yoon-Dong, Scott Terri L, Höltermann Tracey-Ann, Schinazi Raymond F, Chittiboina Prashant, Billioux Bridgette Jeanne, Hammoud Dima A, Olszewski Michal A, Williamson Peter R. Pathway-instructed therapeutic selection of ruxolitinib reduces neuroinflammation in fungal postinfectious inflammatory syndrome.. Science advances. 2025. DOI: 10.1126/sciadv.adi9885.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.